ZVRA — Zevra Therapeutics Share News
0.000.00%
Last trade - 00:00- $613.43m
- $391.86m
- $106.47m
Brief: Zevra Therapeutics Files For Mixed Shelf Offering Of Up To $350 Mln - SEC Filing
Brief: Zevra Therapeutics Announces Positive Final Results From Phase 2 Clinical Trial Of Kp1077 For Idiopathic Hypersomnia
Zevra Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Zevra Therapeutics’ CEO Issues Letter To Stockholders Highlighting Outlook For 2024
Brief: Zevra Therapeutics Presents New Data On The Long-Term Safety And Efficacy Of Arimoclomol
Brief: Zevra Therapeutics Refinances Existing Debt
Zevra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Zevra Therapeutics Announces Top-Line Data From Phase 2 Clinical Trial Of KP1077
Zevra Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
Zevra Therapeutics down as FDA extends review for genetic disorder treatment
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
Zevra Therapeutics down as FDA extends review for genetic disorder treatment
Brief: Zevra Therapeutics Says US FDA Has Extended Review Period For Arimoclomol NDA
Zevra Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih To Board Of Directors
Brief: Zevra Therapeutics Announces Resubmission Of New Drug Application To The U.S. FDA
Brief: Zevra Therapeutics Ended Q3 2023 With $83.4M In Cash, Cash Equivalents, And Investments, Supporting Cash Runway Forecast Into 2026